Difference between revisions of "Bexarotene (Targretin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
(updated links) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.<ref name="insert">[http:// | + | Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.<ref name="insert">[http://targretin.com/pdf/CAPS-PI-Jan18.pdf Bexarotene (Targretin) capsules package insert]</ref><ref>[[Media:Bexarotene.pdf | Bexarotene (Targretin) capsules package insert (locally hosted backup)]]</ref><ref name="insert_gel">[http://targretin.com/pdf/GEL-PI-Jan-18.pdf Bexarotene (Targretin) gel package insert]</ref><ref>[[Media:Bexarotenegel.pdf | Bexarotene (Targretin) gel package insert (locally hosted backup)]]</ref><ref>[http://targretin.com/ Targretin manufacturer's website]</ref> |
<br>Route: PO, topical | <br>Route: PO, topical | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/targretin-bexarotene-342234 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/targretin-bexarotene-342234 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref><ref name="insert_gel"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http:// | + | *[http://targretin.com/pdf/CAPS-PI-Jan18.pdf Bexarotene (Targretin) capsules package insert]<ref name="insert"></ref> |
| + | *[http://targretin.com/pdf/GEL-PI-Jan-18.pdf Bexarotene (Targretin) gel package insert]<ref name="insert_gel"></ref> | ||
*[http://chemocare.com/chemotherapy/drug-info/bexarotene.aspx Bexarotene systemic (Targretin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bexarotene.aspx Bexarotene systemic (Targretin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/bexarotene.aspx Bexarotene systemic (Targretin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bexarotene.aspx Bexarotene systemic (Targretin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bexarotene-systemic-patient-drug-information Bexarotene systemic (Targretin) patient drug information (UpToDate)]</ref> | ||
Revision as of 18:46, 23 May 2019
General information
Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.[1][2][3][4][5]
Route: PO, topical
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]
Diseases for which it is used
Patient drug information
- Bexarotene (Targretin) capsules package insert[1]
- Bexarotene (Targretin) gel package insert[3]
- Bexarotene systemic (Targretin) patient drug information (Chemocare)[6]
- Bexarotene systemic (Targretin) patient drug information (UpToDate)[7]
- Bexarotene topical (Targretin) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 12/29/1999: Initial FDA approval "for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy."
Also known as
- Code name: LGD1069
- Brand names: Bexgratin, Targretin
References
- ↑ 1.0 1.1 1.2 Bexarotene (Targretin) capsules package insert
- ↑ Bexarotene (Targretin) capsules package insert (locally hosted backup)
- ↑ 3.0 3.1 3.2 Bexarotene (Targretin) gel package insert
- ↑ Bexarotene (Targretin) gel package insert (locally hosted backup)
- ↑ Targretin manufacturer's website
- ↑ Bexarotene systemic (Targretin) patient drug information (Chemocare)
- ↑ Bexarotene systemic (Targretin) patient drug information (UpToDate)
- ↑ Bexarotene topical (Targretin) patient drug information (UpToDate)